Interviews

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Nicholas Robert, MD, medical director of data, evidence and insights at McKesson Life Sciences, discusses the FDA’s role in helping providers become comfortable with biosimilars. 
Alexandra Valenti, JD, associate at Goodwin, discusses what drug makers should consider as the United States approaches a regulatory transition for insulins.
Scott Gottlieb, MD, former commissioner of the FDA, discusses whether Congress should make changes to the Biologics Price Competition and Innovation Act (BPCIA) if the opportunity arises. 
Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how biosimilars fit in the treatment paradigm for inflammatory bowel disease (IBD). 
 
Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses whether value-based contracts have a role to play in biosimilar uptake. 
Scott Gottlieb, MD, former commissioner of the FDA, discusses what might become of the Biologics Price Competition and Innovation Act (BPCIA) if the Affordable Care Act (ACA) is invalidated. 
Nicholas Robert, MD, medical director of data, evidence and insights at McKesson Life Sciences, discusses how comfortable oncologists are with using biosimilars.
Alexandra Valenti, JD, associate at Goodwin, discusses common features of some recent high-profile class-action lawsuits over AbbVie’s Humira. 
Scott Gottlieb, MD, former commissioner of the FDA, discusses whether phase 3 trials for biosimilars might eventually be waived in the United States.
Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses ways to increase provider comfort with biosimilars.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.